Header Logo

Connection

MARC HOROWITZ to Humans

Back to Details
This is a "connection" page, showing publications MARC HOROWITZ has written about Humans.
MARC HOROWITZ
Connection Strength
0.109
Humans
  1. Childhood cancer survivor care: development of the Passport for Care. Nat Rev Clin Oncol. 2014 12; 11(12):740-50.
    View in: PubMed
    Score: 0.013
  2. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). J Clin Oncol. 2005 Jan 20; 23(3):525-31.
    View in: PubMed
    Score: 0.007
  3. Stressors and strains of medical training and practice. Swiss Med Wkly. 2003 Dec 13; 133(45-46):629.
    View in: PubMed
    Score: 0.006
  4. Clinician perceptions of Passport for Care, a web-based clinical decision support tool for survivorship care plan delivery. Pediatr Blood Cancer. 2023 01; 70(1):e30070.
    View in: PubMed
    Score: 0.006
  5. Improving Childhood Cancer Survivor Care Through Web-Based Platforms. Oncology (Williston Park). 2018 01 15; 32(1):e1-e10.
    View in: PubMed
    Score: 0.004
  6. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer. 1996 Aug 15; 78(4):901-11.
    View in: PubMed
    Score: 0.004
  7. Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy. J Clin Oncol. 1996 Mar; 14(3):901-10.
    View in: PubMed
    Score: 0.004
  8. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol. 1996 Feb; 14(2):362-72.
    View in: PubMed
    Score: 0.004
  9. A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors. Cancer. 1995 Jun 01; 75(11):2762-7.
    View in: PubMed
    Score: 0.003
  10. Benefit from prolonged dose-intensive chemotherapy for infants with malignant brain tumors is restricted to patients with ependymoma: a report of the Pediatric Oncology Group randomized controlled trial 9233/34. Neuro Oncol. 2014 Mar; 16(3):457-65.
    View in: PubMed
    Score: 0.003
  11. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol. 1993 Oct; 11(10):1911-8.
    View in: PubMed
    Score: 0.003
  12. Pulmonary metastases: MR imaging with surgical correlation--a prospective study. Radiology. 1992 Jan; 182(1):123-9.
    View in: PubMed
    Score: 0.003
  13. Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy. Int J Radiat Oncol Biol Phys. 1991 Mar; 20(3):389-95.
    View in: PubMed
    Score: 0.003
  14. Leadership: "They never taught me this in medical school". J Pediatr Hematol Oncol. 2010 May; 32(4):304-8.
    View in: PubMed
    Score: 0.002
  15. Feasibility and efficacy of preirradiation chemotherapy for pediatric brain tumors. Neurosurgery. 1988 Apr; 22(4):687-90.
    View in: PubMed
    Score: 0.002
  16. Brain tumors in the very young child. Postoperative chemotherapy in combined-modality treatment. Cancer. 1988 Feb 01; 61(3):428-34.
    View in: PubMed
    Score: 0.002
  17. Hepatic undifferentiated (embryonal) sarcoma and rhabdomyosarcoma in children. Results of therapy. Cancer. 1987 Feb 01; 59(3):396-402.
    View in: PubMed
    Score: 0.002
  18. Development and characterization of human ependymoma xenograft HxBr5. Cancer Res. 1987 Jan 15; 47(2):499-504.
    View in: PubMed
    Score: 0.002
  19. Therapy for childhood soft-tissue sarcomas other than rhabdomyosarcoma: a review of 62 cases treated at a single institution. J Clin Oncol. 1986 Apr; 4(4):559-64.
    View in: PubMed
    Score: 0.002
  20. A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group. J Neurooncol. 2006 Apr; 77(2):193-8.
    View in: PubMed
    Score: 0.002
  21. Cumulative renal tubular damage associated with cisplatin nephrotoxicity. Cancer Chemother Pharmacol. 1986; 18(1):69-73.
    View in: PubMed
    Score: 0.002
  22. The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro Oncol. 1999 04; 1(2):152-61.
    View in: PubMed
    Score: 0.001
  23. Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study. Ann Neurol. 1998 Sep; 44(3):313-6.
    View in: PubMed
    Score: 0.001
  24. Reoperative pulmonary metastasectomy for sarcomatous pediatric histologies. Ann Thorac Surg. 1998 Sep; 66(3):908-12; discussion 913.
    View in: PubMed
    Score: 0.001
  25. Prognostic factors in infants and very young children with intracranial ependymomas. Pediatr Neurosurg. 1998 Apr; 28(4):215-22.
    View in: PubMed
    Score: 0.001
  26. Primary malignant rhabdoid tumor of the central nervous system. Ultrastruct Pathol. 1997 Jul-Aug; 21(4):361-8.
    View in: PubMed
    Score: 0.001
  27. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood. Ultrastruct Pathol. 1997 Jul-Aug; 21(4):369-78.
    View in: PubMed
    Score: 0.001
  28. Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol. 1996 Oct; 14(10):2818-25.
    View in: PubMed
    Score: 0.001
  29. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer. 1996 Aug 01; 78(3):527-31.
    View in: PubMed
    Score: 0.001
  30. Treatment of infants with malignant gliomas: the Pediatric Oncology Group experience. J Neurooncol. 1996 May-Jun; 28(2-3):245-56.
    View in: PubMed
    Score: 0.001
  31. Lack of efficacy of postoperative chemotherapy and delayed radiation in very young children with pineoblastoma. Pediatric Oncology Group. Med Pediatr Oncol. 1995 Jul; 25(1):38-44.
    View in: PubMed
    Score: 0.001
  32. Metastasectomy for sarcomatous pediatric histologies: results and prognostic factors. Ann Thorac Surg. 1995 Jun; 59(6):1385-9; discussion 1390.
    View in: PubMed
    Score: 0.001
  33. Atypical cytogenic aberrations in two childhood peripheral primitive neuroectodermal tumors. Genes Chromosomes Cancer. 1995 Feb; 12(2):142-7.
    View in: PubMed
    Score: 0.001
  34. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med. 1995 Jan 19; 332(3):143-9.
    View in: PubMed
    Score: 0.001
  35. Postoperative chemotherapy and delayed radiation in infants and very young children with choroid plexus carcinomas. The Pediatric Oncology Group. Pediatr Neurosurg. 1995; 22(4):189-96.
    View in: PubMed
    Score: 0.001
  36. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood. 1994 Oct 01; 84(7):2221-8.
    View in: PubMed
    Score: 0.001
  37. Immunohistochemical detection of P-glycoprotein in Ewing's sarcoma and peripheral primitive neuroectodermal tumors before and after chemotherapy. Am J Clin Pathol. 1994 Jul; 102(1):61-7.
    View in: PubMed
    Score: 0.001
  38. Sarcomas of the hand and foot: analysis of local control and functional result with combined modality therapy in extremity preservation. Int J Radiat Oncol Biol Phys. 1994 Jul 01; 29(4):735-45.
    View in: PubMed
    Score: 0.001
  39. Desmoplastic infantile gangliogliomas: an approach to therapy. Neurosurgery. 1994 Apr; 34(4):583-9; discussion 589.
    View in: PubMed
    Score: 0.001
  40. Malignant schwannoma with melanocytic and neuroepithelial differentiation in an infant with congenital giant melanocytic nevus: a complex neurocristopathy. Hum Pathol. 1993 Dec; 24(12):1371-5.
    View in: PubMed
    Score: 0.001
  41. A phase II evaluation of thiotepa in pediatric central nervous system malignancies. Cancer. 1993 Jul 01; 72(1):271-5.
    View in: PubMed
    Score: 0.001
  42. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med. 1993 Jun 17; 328(24):1725-31.
    View in: PubMed
    Score: 0.001
  43. Response of pediatric low grade gliomas to chemotherapy. Pediatr Neurosurg. 1993 May-Jun; 19(3):113-8; discussion 119-20.
    View in: PubMed
    Score: 0.001
  44. Cytogenetic studies in subgroups of rhabdomyosarcoma. Genes Chromosomes Cancer. 1992 Nov; 5(4):299-310.
    View in: PubMed
    Score: 0.001
  45. Expression of the cholecystokinin gene in pediatric tumors. Proc Natl Acad Sci U S A. 1992 Jul 01; 89(13):5819-23.
    View in: PubMed
    Score: 0.001
  46. Neuraxis dissemination in pediatric brain tumors. Response to preirradiation chemotherapy. Cancer. 1992 Feb 15; 69(4):1061-6.
    View in: PubMed
    Score: 0.001
  47. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst. 1991 Oct 16; 83(20):1460-70.
    View in: PubMed
    Score: 0.001
  48. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relat Res. 1991 Sep; (270):8-14.
    View in: PubMed
    Score: 0.001
  49. Thermal effects on heart rate of the neonate. Am J Obstet Gynecol. 1971 Jul 01; 110(5):674-6.
    View in: PubMed
    Score: 0.001
  50. Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from the multiinstitutional osteosarcoma study. J Clin Oncol. 1991 Apr; 9(4):600-5.
    View in: PubMed
    Score: 0.001
  51. Phase II trial of sequential methotrexate and 5-fluorouracil with leucovorin in children with sarcomas. Invest New Drugs. 1990 May; 8(2):181-2.
    View in: PubMed
    Score: 0.001
  52. Intensive combined modality therapy of small round cell and undifferentiated sarcomas in children and young adults: local control and patterns of failure. Radiother Oncol. 1989 Nov; 16(3):189-201.
    View in: PubMed
    Score: 0.001
  53. Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988. Semin Oncol. 1989 Feb; 16(1 Suppl 3):51-5.
    View in: PubMed
    Score: 0.001
  54. The impact of delayed surgery on radiotherapy dose and local control of rhabdomyosarcoma. Arch Surg. 1987 Dec; 122(12):1451-4.
    View in: PubMed
    Score: 0.001
  55. Challenges in the treatment of childhood fibromatosis. Arch Surg. 1987 Nov; 122(11):1296-8.
    View in: PubMed
    Score: 0.001
  56. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy. Cancer Res. 1987 Mar 01; 47(5):1457-60.
    View in: PubMed
    Score: 0.000
  57. Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna. Cancer Treat Rep. 1987 Feb; 71(2):127-30.
    View in: PubMed
    Score: 0.000
  58. Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep. 1987 Feb; 71(2):131-5.
    View in: PubMed
    Score: 0.000
  59. Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity. Cancer Chemother Pharmacol. 1987; 19(1):57-60.
    View in: PubMed
    Score: 0.000
  60. Enhancement of methotrexate nephrotoxicity after cisplatin therapy. Cancer. 1986 Dec 15; 58(12):2617-21.
    View in: PubMed
    Score: 0.000
  61. Cancer chemotherapy-induced tubular nephrotoxicity evaluated by immunochemical determination of urinary adenosine deaminase binding protein. Am J Clin Pathol. 1986 Dec; 86(6):780-3.
    View in: PubMed
    Score: 0.000
  62. Combination of dacarbazine and doxorubicin in the treatment of childhood rhabdomyosarcoma. Cancer Treat Rep. 1985 Sep; 69(9):999-1000.
    View in: PubMed
    Score: 0.000
  63. Chromosome 1 abnormalities: a common feature of pediatric solid tumors. J Natl Cancer Inst. 1985 Jul; 75(1):51-4.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.